2025-05-27 - Analysis Report
Okay, here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the provided data, formatted for a professional report.

**Johnson & Johnson (JNJ) Stock Analysis**

**1. Performance Overview vs. S&P 500 (VOO)**

*   **Ticker:** JNJ
*   **Company Overview:** Johnson & Johnson is a global healthcare company engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field.

*   **Key Performance Figures:**
    *   JNJ Cumulative Return: 18.74%
    *   VOO (S&P 500) Cumulative Return: 79.45%
    *   Absolute Performance Difference: -60.71%
    *   Range of Historical Performance Difference: Max: 17.5%, Min: -76.4%
    *   Relative Performance Difference (Current Position): 16.7%

*   **Analysis:** JNJ has significantly underperformed the S&P 500 (VOO) over the period examined. The cumulative return difference is substantial. A relative performance difference of 16.7% suggests JNJ's underperformance is near the lower end of its historical range compared to VOO.

*   **Alpha and Beta Analysis:**

    | Year       | CAGR     | MDD      | Alpha  | Beta | Cap(B) |
    |------------|----------|----------|--------|------|--------|
    | 2015-2017  | 28.0%    | 56.0%    | -1.0%  | 0.0  | 274.9  |
    | 2016-2018  | 10.0%    | 10.8%    | -7.0%  | 0.0  | 260.8  |
    | 2017-2019  | 20.0%    | 10.8%    | -9.0%  | 0.7  | 303.1  |
    | 2018-2020  | 14.0%    | 59.8%    | -12.0% | 0.5  | 335.9  |
    | 2019-2021  | 28.0%    | 59.9%    | -26.0% | 0.3  | 374.3  |
    | 2020-2022  | 4.0%     | 61.2%    | -2.0%  | 0.3  | 396.7  |
    | 2021-2023  | -19.0%   | 61.2%    | -35.0% | 0.4  | 362.6  |
    | 2022-2024  | -31.0%   | 61.2%    | -47.0% | 0.3  | 345.2  |
    | 2023-2025  | -8.0%    | 69.6%    | -35.0% | 0.2  | 368.0  |

    *   **CAGR:** The Compound Annual Growth Rate (CAGR) varies significantly across the periods. Recent periods (2021-2025) show negative growth.
    *   **MDD:** The Maximum Drawdown (MDD) indicates the largest peak-to-trough decline during the period. MDD is notably high in recent years, suggesting increased volatility.
    *   **Alpha:**  The negative Alpha values consistently indicate underperformance relative to the benchmark (S&P 500). The underperformance has been particularly pronounced in recent years.
    *   **Beta:** The Beta values are relatively low, suggesting that JNJ has historically been less volatile than the market.
    *   **Cap(B):** The market capitalization (in billions) shows growth initially but has seen some decline in recent periods, reflecting market performance and possibly company-specific factors.

**2. Recent Price Movements**

*   **Current Price:** $152.94
*   **Last Market Data:**
    *   Price: $152.94
    *   Previous Close: $152.61
    *   Change: $0.22
*   **Moving Averages:**
    *   5-day Moving Average: $152.98
    *   20-day Moving Average: $153.48
    *   60-day Moving Average: $157.59

*   **Analysis:**  The stock price has shown a slight increase in the last trading session. However, the price is trading below its 20-day and 60-day moving averages, suggesting a short-term downward trend.

**3. Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 45.52 (Neutral)
*   **PPO:** 0.13 (Neutral)
*   **Hybrid Signal:** Cash_1%_Buy 80% of cash (22 shares - Caution - MRI:0.37)
*   **Recent (20-day) Relative Performance Difference Change:** 4.9 (+) - Short-term Increase
*   **Expected Return:** -150.9% (Long-Term Underperformance vs. S&P 500)

*   **Analysis:**
    *   The Market Risk Indicator suggests a low-risk environment for the stock.
    *   The RSI is near the neutral level, indicating neither overbought nor oversold conditions.
    *   The PPO is slightly positive.
    *   The Hybrid Signal suggests a cautious buying opportunity, based on the current market conditions and MRI.
    *   The recent increase in relative performance difference suggests some short-term positive momentum.
    *   The significantly negative expected return indicates that, if the current trend continues, JNJ is expected to substantially underperform the S&P 500 over the long term (2+ years).
    *   **The fact that {'price': 152.94, 'previousClose': 152.61, 'change': 0.22} is very small reflects only a slight upward price movement.**

**4. Recent News & Significant Events**

*   **[2025-05-24]:** Major business developments, regulatory changes, or market events impacting Johnson & Johnson.
*   **[2025-05-26]:** Analyst discussions on JNJ's recent performance, industry trends, and global economic factors.
*   **[2025-05-23]:** Stock volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-05-25]:** Market experts highlighting risks and opportunities, advising monitoring of news and announcements.

*   **Analysis:** Recent news indicates that JNJ is experiencing significant events that are impacting its stock performance. These events include regulatory changes, market volatility, and analyst discussions. Investors should closely monitor these developments.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2024-07-25 | 1.95 | 22.45 B$   |
| 2024-05-01 | 1.35 | 21.38 B$   |
| 2025-04-23 | 1.35 | 21.38 B$   |

*   **Analysis:** The EPS (Earnings Per Share) has fluctuated. While the latest reported EPS is relatively high, the values have varied significantly over the past year. Revenue has also shown some variation, indicating potential inconsistencies in the company's financial performance.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |
| 2024-06-30   | $22.45B    | 69.40%        |
| 2024-03-31   | $21.38B    | 69.55%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE      |
|--------------|-------------|----------|
| 2025-03-31   | $78.11B     | 14.08%   |
| 2024-12-31   | $71.49B     | 4.80%    |
| 2024-09-30   | $70.16B     | 3.84%    |
| 2024-06-30   | $71.54B     | 6.55%    |
| 2024-03-31   | $70.02B     | 4.65%    |

*   **Analysis:**
    *   **Revenue and Profitability:** Revenue has been relatively stable but shows some variability. The profit margin has slightly decreased over the past year.
    *   **Capital and Profitability:** Equity has increased significantly in the most recent quarter. The ROE (Return on Equity) is highly variable, with a significant increase in the latest quarter.

**7. Overall Summary and Conclusion**

Based on the provided data, Johnson & Johnson (JNJ) is currently underperforming the S&P 500. The negative alpha values and significantly negative expected return highlight this underperformance. Recent earnings data and financial information show mixed results, with fluctuating EPS and revenue, and variable ROE.

While the Market Risk Indicator suggests a low-risk environment, investors should be cautious due to the negative long-term outlook and recent volatility. The recent news indicates that JNJ is experiencing significant events that are impacting its stock performance.

**Recommendation:**

Given the underperformance, investors should exercise caution and closely monitor the company's performance, recent news, and industry trends. The Hybrid Signal suggests a cautious buying opportunity, but investors should consider the negative long-term outlook before making any investment decisions. Further investigation into the reasons for the negative alpha and expected return is recommended.
